scorecardresearch
Add as a preferred source on Google
Wednesday, January 7, 2026
TopicAnti-cancer drugs

Topic: anti-cancer drugs

Drug costs form chunk of out-of-pocket spending on health in India. This could change with GST reforms

The Union Finance Ministry announced a five percent GST on all drugs and medicines from 22 September—down from the earlier 12 percent GST.

PGIMER report bats for new-age targeted lung cancer therapies to be included in AB-PMJAY

Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly diagnosed advanced or metastatic non-small cell lung cancer.

Months after import duty waiver, GST slashed on same 3 anti-cancer drugs. Why this is little relief

Centre moves to reduce costs of trastuzumab deruxtecan, osimertinib & durvalumab, all 3 by British-Swedish pharma giant AstraZeneca. Doctors seek exemptions for more such drugs. 

On Camera

A 2-hour op, precise extradition—what Maduro’s capture tells us about modern US military

Despite multiple agencies being involved, the US could maintain a clear chain of command. This is something India should consider too, as it defines the theatre command structures.

Trump threatens India with fresh tariffs on Russian oil, calls PM Modi a ‘good guy’

The latest comment comes as New Delhi and Washington have yet to sign a trade agreement. India’s purchase of Russian oil has reduced, but Moscow remains top source for crude.

S-300, Su-30 jets, T-72 tanks: Inventory of Venezuela’s largely Russian-origin arsenal

Venezuela also boasts of a diverse portfolio of unmanned aerial vehicles capable of carrying out surveillance, reconnaissance and being employed for kinetic purposes as well.

A year-end Mea Culpa in National Interest—The Army-Islam combo doesn’t kill democracy

Many of you might think I got something so wrong in National Interest pieces written this year. I might disagree! But some deserve a Mea Culpa. I’d deal with the most recent this week.